Thursday, September 02, 2010

Breast Cancer

HLMCC 0806
Phase II Placebo Controlled Trial of Lisinopril and Coreg to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)Adjuvant Chemotherapy with Herceptin
CALGB-40101	Lead group: CALGB
Cyclophosphamide and Doxorubicin (CA) (4 vs. 6 Cycles) Versus Paclitaxel (4 vs. 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2X2 Factorial Phase III Randomized Study
NSABP-B-39	Lead Group: NSABP
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
PACCT-1	Lead Group: ECOG
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial
CALGB 40502
A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB- Paclitaxel or Ixabepilone Combined with Bevacizumab as First -Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
NSABP B-43
A Phase III Clinical Trial Comparing Trastuzumab (Herceptin) Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situ Resected by Lumpectomy.

We participate in many NCI sponsored trials. Please feel free to contact Leann Ross at (304) 399-6617 or leann.ross@chhi.org or Barbara Payne at (304) 399-6637.

For more information about the clinical trials listed please go to http://www.clinicaltrials.gov.